5.25 USD
▲+0.20+4.37%
2026-08-03
市值
$50.84M
市盈率
—
EPS
-5.17
股息率
—
52 周区间
4.59 – 29.98
成交量
40.46K
Beta
0.23
目标价
17.00
52W 低 4.5952W 高 29.98
价格走势
公司简介
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI...